Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL657651 | 1.00 | MPO (0.43) | MPOMETRETACHEKDM5B | |
| SCHEMBL2028023 | 0.87 | MPO (0.41) | MPOMET | |
| SCHEMBL660315 | 0.81 | MET (0.41) | METRETACHE | |
| SCHEMBL660314 | 0.81 | MET (0.41) | METRETACHE | |
| SCHEMBL658738 | 0.79 | FFAR1 (0.43) | MET | |
| SCHEMBL659363 | 0.79 | FFAR1 (0.43) | MET | |
| SCHEMBL670597 | 0.78 | — | — | |
| SCHEMBL31392849 | 0.77 | MPO (0.37) | MPO | |
| SCHEMBL1357653 | 0.75 | MET (0.33) | MET | |
| SCHEMBL1357654 | 0.75 | MET (0.33) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. | 2025-08-28 | — | — | US | disclosed |
| US-12351581-B2 | Compounds for FGFR inhibition | COGENT BIOSCIENCES, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025034912-A9 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250066352-A1 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. | 2025-02-27 | — | — | US | disclosed |
| WO-2025034912-A2 | COMPOUNDS FOR FGFR INHIBITION | COGENT BIOSCIENCES, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-2569314-B1 | FUSED BICYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-9096624-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals ,LLC | 2014-03-27 | — | — | US | disclosed |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8445510-B2 | Fused bicyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2013-05-21 | — | — | US | disclosed |
| US-20130072495-A1 | FUSED BICYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC | 2013-03-21 | — | — | US | disclosed |
| US-8399433-B2 | Amino pyrimidine anticancer compounds | OSI Pharmaceuticals, LLC (US) | 2013-03-19 | — | — | US | disclosed |
| US-8378104-B2 | 7-aminofuropyridine derivatives | OSI Pharmaceuticals, LLC (US) | 2013-02-19 | — | — | US | disclosed |
| EP-2438056-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI Pharmaceuticals, LLC (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | OSI PHARMACEUTICALS, INC. | 2012-02-23 | — | — | US | disclosed |
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | OSI Pharmaceuticals, LLC | 2011-11-17 | — | — | US | disclosed |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
| WO-2010141406-A2 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2010-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281888-A1 | Fused Bicyclic Kinase Inhibitors | ALK, RET, MET | MPO 4233/4885MET 3/4885RET 2/4885 |
| US-20130253197-A1 | FUSED BICYCLIC KINASE INHIBITORS | ALK, RET, MET | MPO 4233/4885MET 3/4885RET 2/4885 |
| US-20250066352-A1 | COMPOUNDS FOR FGFR INHIBITION | FGFR1, FGFR4, FGFR3 | MPO 4883/4885MET 15/4885RET 12/4885 |
| US-20130231306-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | MPO 4636/4885MET 585/4885RET 402/4885 |
| US-20250270211-A1 | COMPOUNDS FOR FGFR INHIBITION | FGFR1, FGFR4, FGFR3 | MPO 4883/4885MET 15/4885RET 12/4885 |
| US-20120046267-A1 | 7-AMINOFUROPYRIDINE DERIVATIVES | MAP3K5, STK17A, MAPKAPK5 | MPO 3843/4885MET 1182/4885RET 588/4885 |
| US-20130072495-A1 | FUSED BICYCLIC KINASE INHIBITORS | IGF1R, MET, ALK | MPO 4657/4885MET 2/4885RET 4/4885 |
| US-20110136764-A1 | AMINO PYRIMIDINE ANTICANCER COMPOUNDS | DPYD, PTK2, TYMS | MPO 4636/4885MET 585/4885RET 402/4885 |
| US-12351581-B2 | Compounds for FGFR inhibition | FGFR1, FGFR4, FGFR3 | MPO 4883/4885MET 15/4885RET 12/4885 |
| US-20140088114-A1 | FUSED BICYCLIC KINASE INHIBITORS | IGF1R, MET, RET | MPO 4641/4885MET 2/4885RET 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.